Goldman Sachs Highlights BioNTech’s (BNTX) Immuno-Oncology and ADC Pipeline

BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy and boosted its price target from $115 to $142, highlighting the company’s key position in oncology. According to the firm, BioNTech SE stands “at the nexus of significant developments occurring in the oncology field,” particularly in next-generation immuno-oncology and antibody-drug conjugates (ADCs).

Zoetis (ZTS) Hits New 52-Week Low on Dismal Outlook

Goldman Sachs noted BioNTech’s extensive portfolio of programs aimed at an estimated market worth more than $100 billion, with key results coming in 2026 that could position the company as a pioneer in the next stage of oncology treatments.

However, Goldman Sachs recognized potential rivalry in BioNTech’s clinical development domains, including competition from other bispecific antibody companies and late-stage ADC initiatives. However, it determined that BioNTech has a “unique risk/reward opportunity” in the rapidly changing oncology field.

BioNTech SE is a German biotechnology company that develops and commercializes novel immunotherapies and vaccines for cancer and infectious diseases.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

This article is originally published at Insider Monkey.